| Tammy Lynn Winford, CSFA | |
|
1314 W Mcdermott Dr Ste 106-608, Allen, TX 75013-3021 | |
| (214) 383-2770 | |
| (214) 383-2771 |
| Full Name | Tammy Lynn Winford |
|---|---|
| Gender | Female |
| Speciality | Surgery |
| Location | 1314 W Mcdermott Dr Ste 106-608, Allen, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932693710 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 159589 (Oklahoma) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Tammy Lynn Winford, CSFA 1314 W Mcdermott Dr Ste 106-608, Allen, TX 75013-3021 Ph: (214) 383-2770 | Tammy Lynn Winford, CSFA 1314 W Mcdermott Dr Ste 106-608, Allen, TX 75013-3021 Ph: (214) 383-2770 |
News Archive
40,000 high school football kids get a concussion every year, but contrary to equipment manufacturers' claims, the specific brand of helmet and helmet age were not associated with lower risk of concussion, say researchers presenting their work today at the American Orthopaedic Society for Sports Medicine's Annual Meeting in Chicago, IL.
More than a dozen states have passed legislation expanding the role of nurse practitioners (NPs) so they can help fill the shortage of primary care providers in the U.S. But a new study from Columbia University School of Nursing, published in the Journal of Professional Nursing, suggests that the organization and culture in health care settings often impedes the full utilization of NPs so that state laws expanding scope of practice may not be sufficient to relieve the nation's primary care crisis.
Valeant Pharmaceuticals International, Inc. announced today that Alexza Pharmaceuticals, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug Application (NDA) for AZ-004 (Staccato® loxapine) submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg.
Abbott has announced it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S. and juvenile idiopathic arthritis (JIA) in the European Union (EU).
› Verified 7 days ago
Robert H Connaughton, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1105 Central Expy N Ste 350, Allen, TX 75013 Phone: 692-848-9904 Fax: 469-382-9362 | |
Mrs. Brittani Bell, CST Surgery Medicare: Not Enrolled in Medicare Practice Location: 1105 Central Expy N, Allen, TX 75013 Phone: 918-955-5087 | |
Radha Gopal Iyengar, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1105 Central Expy N Ste 2100, Medical Building 2, Allen, TX 75013 Phone: 972-747-6401 Fax: 972-747-6405 | |
Nam Hoai Le, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1105 Central Expy N Ste 2370, Allen, TX 75013 Phone: 972-747-4271 Fax: 972-747-4272 |